接受精神疾病药物治疗的青少年中细胞色素P450表型转换的患病率估计
该研究在1281名6-24岁接受精神疾病药物治疗并完成CYP2B6、CYP2C19、CYP2D6、CYP3A4药物基因组检测的青少年中估计表型转换患病率。近半数(46%)队列在四个基因之一存在表型转换;校正表型转换后,CYP2C19、CYP2D6和CYP3A4的可操作表型显著增多。发生表型转换者中24%的代谢表型改变会使现行药物基因组处方指南推荐调整标准处方。
要点
- 近半数接受精神疾病药物治疗的青少年存在CYP450表型转换。
- 校正表型转换后CYP2C19、CYP2D6、CYP3A4可操作表型显著增多。
- 表型转换者中24%的代谢表型改变影响现行指南处方推荐。
核心结论
- 接受精神疾病药物治疗的青少年中细胞色素P450表型转换患病率较高。
- 在青少年中实施药物基因组检测时应考虑校正表型转换以提高临床效用。
研究设计与样本
- 研究纳入1281名6-24岁接受精神疾病药物治疗并完成CYP2B6、CYP2C19、CYP2D6、CYP3A4药物基因组检测的青少年。
- 在药物基因组检测时收集自我报告的用药及大麻二酚/大麻使用情况。
主要发现
- 近半数(46%)队列在四个基因之一被估计存在表型转换。
- 校正表型转换后CYP2C19可操作表型由60.3%增至69.1%(P=<0.001)。
- 校正表型转换后CYP2D6可操作表型由49.3%增至63.0%(P=<0.001)。
- 校正表型转换后CYP3A4可操作表型由8.5%增至12.2%(P=0.003)。
- 发生表型转换的青少年中24%的代谢表型改变会使现行药物基因组处方指南推荐调整标准处方(剂量调整、换药)。
临床怎么用
- 在青少年中实施药物基因组检测时,应考虑校正表型转换以提升检测的临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacogenetics-predicted drug metabolism may not match clinically observed metabolism due to a phenomenon known as phenoconversion. Phenoconversion can occur when an inhibitor or inducer of a drug-metabolizing enzyme is present. Although estimates of phenoconversion in adult populations are available, prevalence estimates in youth populations are limited. To address this gap, we estimated the prevalence of phenoconversion in 1281 youth (6-24 years) receiving pharmacotherapy for mental health conditions and who had pharmacogenetics testing completed for four genes (CYP2B6, CYP2C19, CYP2D6, CYP3A4). Self-reported medication and cannabidiol/cannabis use were collected at the time of pharmacogenetics testing. Nearly, half (46%) of the cohort was estimated to be phenoconverted for one of the four genes examined. Comparison of metabolizer phenotype frequencies before and after adjustment for phenoconversion showed significantly more youth had actionable phenotypes for CYP2C19 (60.3% vs. 69.1%; P =< 0.001), CYP2D6 (49.3% vs. 63.0%; P =< 0.001), and CYP3A4 (8.5% vs.12.2%; P = 0.003) after phenoconversion adjustment. Of youth who were phenoconverted, 24% had a change in their metabolizer phenotype that would lead to current pharmacogenetics-based prescribing guidelines recommending a change to standard prescribing (dose adjustment, alternative medication). Our findings indicate a high prevalence of cytochrome P450 phenoconversion among youth receiving pharmacotherapy for mental health conditions. Adjustment for phenoconversion should be considered when implementing pharmacogenetics testing in youth populations to improve the clinical utility of this testing in practice.
引用
- Gerlach S, Maruf AA, Shaheen SM, et al. Prevalence Estimates of Cytochrome P450 Phenoconversion in Youth Receiving Pharmacotherapy for Mental Health Conditions. Clin Pharmacol Ther. 2024. PMID: 39686785. doi:10.1002/cpt.3534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。